Centessa plans $100m IPO to fund R&D and potential acquisitionsCentessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in Share XCentessa plans $100m IPO to fund R&D and potential acquisitionshttps://pharmaphorum.com/news/centessa-plans-100m-ipo-to-fund-rd-and-potential-acquisitions/
Slaoui exits three more companies amid harassment falloutMoncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm Share XSlaoui exits three more companies amid harassment fallouthttps://pharmaphorum.com/news/slaoui-exits-three-more-companies-amid-harassment-fallout/
GSK fires former R&D chief Slaoui after sexual harassment allegationGlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it Share XGSK fires former R&D chief Slaoui after sexual harassment allegationhttps://pharmaphorum.com/news/gsk-fires-former-rd-chief-slaoui-after-sexual-harassment-allegation/
Centessa’s founder on the new company’s unique R&D modelPutting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted Share XCentessa’s founder on the new company’s unique R&D modelhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/centessa-founder-companys-unique-rd-model/
Mega biotech Centessa beams up ex-Warp Speed science chief SlaouiOperation Warp Speed’s former science chief Moncef Slaoui is to lead research at a new mega-biotech called Centessa, Share XMega biotech Centessa beams up ex-Warp Speed science chief Slaouihttps://pharmaphorum.com/news/slaoui-launches/
